AllPennyStocks.com Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock

Berenberg sees potential upside to Lilly’s full-year 2026 revenue forecast, which ranges from $85 billion to $87 billion.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
Maiden Drill Campaign at Onuki Zone Concludes Under Sumitomo Earn-In
High-Grade 190 g/t Gold Grab Sample Highlights Manitoba Quartz Vein Expansion
Most Popular
{{ index + 1 }}


Back to Top